首页> 美国卫生研究院文献>other >Ultrasound-Mediated Destruction of LHRHa Targeted and Paclitaxel Loaded Lipid Microbubbles Induces Proliferation Inhibition and Apoptosis in Ovarian Cancer Cells
【2h】

Ultrasound-Mediated Destruction of LHRHa Targeted and Paclitaxel Loaded Lipid Microbubbles Induces Proliferation Inhibition and Apoptosis in Ovarian Cancer Cells

机译:超声介导的LHRHa靶向和紫杉醇加载脂质微泡的破坏诱导卵巢癌细胞的增殖抑制和凋亡。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although paclitaxel (PTX) is used with platinum as the first line chemotherapy regimen for ovarian cancer, its clinical efficacy is often limited by severe adverse effects. Ultrasound targeted microbubble destruction (UTMD) technique holds a great promise in minimizing the side effects and maximizing the therapeutic efficacy. However, the technique typically uses non-targeted microbubbles with suboptimal efficiency. We synthesized targeted and PTX-loaded microbubbles (MBs) for UTMD mediated chemotherapy in ovarian cancer cells. PTX-loaded lipid MBs were coated with a luteinizing hormone-releasing hormone analogue (LHRHa) through a biotin-avidin linkage to target the ovarian cancer A2780/DDP cells that express the LHRH receptor. In the cell culture studies, PTX-loaded and LHRHa targeted MBs (TPLMBs) in combination with ultrasound (300 kHz, 0.5 W/cm2, 30 seconds) demonstrated anti-proliferative activities of 41.30 ± 3.93%, 67.76 ± 2.45%, and 75.93 ± 2.81% at 24 hours, 48 hours, and 72 hours after the treatment, respectively. The cell apoptosis ratio at 24 hours after the treatment is 32.6 ± 0.79 %, which is significantly higher than other treatment groups such as PTX only and no-targeted PTX-loaded MBs (NPLMBs) with or without ultrasound mediation. Our experiment verifies the hypothesis that ultrasound mediation of ovarian cancer targeted and drug loaded MBs will enhance the PTX therapeutic efficiency.
机译:尽管紫杉醇(PTX)与铂一起用作卵巢癌的一线化疗方案,但其临床疗效通常受到严重不良反应的限制。超声靶向微泡破坏(UTMD)技术在最大程度减少副作用和最大化治疗功效方面具有广阔的前景。但是,该技术通常使用次优效率的非目标微气泡。我们合成了靶向和PTX加载的微泡(MBs),用于UTMD介导的卵巢癌细胞化疗。通过生物素-亲和素连接,用促黄体激素释放激素类似物(LHRHa)包被PTX的脂质MBs靶向表达LHRH受体的卵巢癌A2780 / DDP细胞。在细胞培养研究中,载有PTX和LHRHa的目标MB(TPLMB)结合超声(300 kHz,0.5 W / cm 2 ,30秒)表现出41.30±3.93%的抗增殖活性在治疗后的24小时,48小时和72小时分别为67.76±2.45%和75.93±2.81%。治疗后24小时的细胞凋亡率为32.6±0.79%,明显高于其他治疗组,例如仅PTX和无靶向PTX负载的MBs(NPLMB),有或没有超声介导。我们的实验验证了以下假设:超声介导的靶向卵巢癌和载药的MBs将增强PTX的治疗效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号